Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis

医学 脂肪性肝炎 肝活检 肝硬化 脂肪肝 内科学 安慰剂 脂肪变性 临床试验 纤维化 胃肠病学 活检 病理 疾病 替代医学
作者
Stephen A. Harrison,Vlad Ratziu,Quentin M. Anstee,Mazen Noureddin,Arun J. Sanyal,Jörn M. Schattenberg,Pierre Bédossa,Mustafa R. Bashir,David J. Schneider,Rebecca Taub,Meena B. Bansal,Kris V. Kowdley,Zobair M. Younossi,Rohit Loomba
出处
期刊:Alimentary Pharmacology & Therapeutics [Wiley]
卷期号:59 (1): 51-63 被引量:67
标识
DOI:10.1111/apt.17734
摘要

Summary Background Non‐alcoholic steatohepatitis (NASH) is a progressive form of non‐alcoholic fatty liver disease (NAFLD) associated with steatosis, hepatocellular injury, inflammation and fibrosis. In a Phase 2 trial in adults with NASH (NCT02912260), resmetirom, an orally administered, liver‐targeted thyroid hormone receptor‐β selective agonist, significantly reduced hepatic fat (via imaging) and resolved NASH without worsening fibrosis (via liver biopsy) in a significant number of patients compared with placebo. Aims To present the design of the Phase 3 MAESTRO clinical programme evaluating resmetirom for treatment of NASH (MAESTRO‐NAFLD‐1 [NCT04197479], MAESTRO‐NAFLD‐OLE [NCT04951219], MAESTRO‐NASH [NCT03900429], MAESTRO‐NASH‐OUTCOMES [NCT05500222]). Methods MAESTRO‐NASH is a pivotal serial biopsy trial in up to 2000 adults with biopsy‐confirmed at‐risk NASH. Patients are randomised to a once‐daily oral placebo, 80 mg resmetirom, or 100 mg resmetirom. Liver biopsies are conducted at screening, week 52 and month 54. MAESTRO‐NAFLD‐1 is a 52‐week safety trial in ~1400 adults with NAFLD/presumed NASH (based on non‐invasive testing); ~700 patients from MAESTRO‐NAFLD‐1 are enrolled in MAESTRO‐NAFLD‐OLE, a 52‐week active treatment extension to further evaluate safety. MAESTRO‐NASH‐OUTCOMES is enrolling 700 adults with well‐compensated NASH cirrhosis to evaluate the potential for resmetirom to slow progression to hepatic decompensation events. Non‐invasive tests (biomarkers, imaging) are assessed longitudinally throughout, in addition to validated patient‐reported outcomes. Conclusion The MAESTRO clinical programme was designed in conjunction with regulatory authorities to support approval of resmetirom for treatment of NASH. The surrogate endpoints, based on week 52 liver biopsy, serum biomarkers and imaging, are confirmed by long‐term clinical liver‐related outcomes in MAESTRO‐NASH (month 54) and MAESTRO‐NASH‐OUTCOMES (time to event).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
冰勾板勾完成签到,获得积分10
刚刚
今后应助zhuling采纳,获得10
刚刚
魔幻的雁风完成签到,获得积分10
刚刚
淅淅沥沥完成签到,获得积分10
刚刚
荔枝完成签到,获得积分10
刚刚
刚刚
欢呼的觅露完成签到,获得积分10
刚刚
gyhmm完成签到,获得积分10
刚刚
3123939715完成签到,获得积分10
刚刚
拿抓抓拿发布了新的文献求助10
1秒前
1秒前
英勇语蓉完成签到,获得积分10
1秒前
黑山羊完成签到,获得积分10
1秒前
153完成签到,获得积分10
1秒前
隐形曼青应助合适的猎豹采纳,获得10
2秒前
贾明灵完成签到,获得积分10
2秒前
紫色的云完成签到,获得积分10
2秒前
Jaylou完成签到,获得积分0
2秒前
量子星尘发布了新的文献求助10
2秒前
AL完成签到,获得积分10
3秒前
Faded完成签到 ,获得积分10
3秒前
季文婷完成签到,获得积分10
3秒前
桃子完成签到,获得积分10
3秒前
3秒前
cx发布了新的文献求助50
3秒前
3秒前
飞飞完成签到,获得积分10
3秒前
太叔明辉发布了新的文献求助10
4秒前
笑羽完成签到,获得积分0
4秒前
啊炜完成签到 ,获得积分10
4秒前
英勇语蓉发布了新的文献求助10
4秒前
Lucas应助醉熏的含烟采纳,获得10
4秒前
犹豫的夏旋完成签到 ,获得积分10
5秒前
随缘完成签到,获得积分10
5秒前
aaa啊啊啊完成签到,获得积分10
5秒前
5秒前
5秒前
感性的俊驰完成签到 ,获得积分10
6秒前
赘婿应助HH采纳,获得10
6秒前
南至完成签到,获得积分10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
List of 1,091 Public Pension Profiles by Region 1621
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] | NHBS Field Guides & Natural History 1500
Lloyd's Register of Shipping's Approach to the Control of Incidents of Brittle Fracture in Ship Structures 1000
Brittle fracture in welded ships 1000
Metagames: Games about Games 700
King Tyrant 680
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5573758
求助须知:如何正确求助?哪些是违规求助? 4660031
关于积分的说明 14727408
捐赠科研通 4599888
什么是DOI,文献DOI怎么找? 2524520
邀请新用户注册赠送积分活动 1494877
关于科研通互助平台的介绍 1464977